<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01296412</url>
  </required_header>
  <id_info>
    <org_study_id>0431-403</org_study_id>
    <nct_id>NCT01296412</nct_id>
  </id_info>
  <brief_title>Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)</brief_title>
  <official_title>A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to compare the effectiveness and safety of two treatment paradigms
      (oral sitagliptin with or without glimepiride versus liraglutide with or without increased
      dosing) for the treatment of participants with Type 2 Diabetes that is not adequately
      controlled with metformin alone. The primary hypothesis postulated that the mean change from
      baseline in hemoglobin A1c (A1C) in participants treated with a sitagliptin-based treatment
      is non-inferior to that of participants treated with a liraglutide-based

      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 11, 2011</start_date>
  <completion_date type="Actual">February 29, 2012</completion_date>
  <primary_completion_date type="Actual">February 29, 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Hemoglobin A1c (A1C)</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>A1C is measured as percent. Thus, this change from baseline reflects the Week 26 A1C percent minus the Week 0 A1C percent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG)</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>Change from baseline at Week 26 is defined as Week 26 minus Week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reaching A1C Goal of &lt;7.0%</measure>
    <time_frame>Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reaching A1C Goal of &lt;6.5%</measure>
    <time_frame>Week 26</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">653</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Sitagliptin +/- glimepiride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitagliptin 100 mg tablet orally once daily for 26 weeks. Participants continued their stable dose of metformin &gt;=1500 mg orally daily. Participants may have received glimepiride orally for glycemic control.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liraglutide subcutaneous injection once daily for 26 weeks (starting dose 0.6 mg daily up-titrated to 1.2 mg daily on Day 8). Participants continued their stable dose of metformin &gt;=1500 mg orally daily. Participants may have had their liraglutide dose uptitrated to 1.8 mg daily for glycemic control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin</intervention_name>
    <description>100 mg tablet, orally, once daily.</description>
    <arm_group_label>Sitagliptin +/- glimepiride</arm_group_label>
    <other_name>MK-0431, Januvia®, Tesavel®, Xelevia®, Ristaben®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>0.6 mg by subcutaneous (pen) injection, once daily, on Days 1-7; up-titrated on Day 8 to 1.2 mg daily. At Week 12, dose may be increased to 1.8 mg once daily for participants who did not meet protocol-specified glycemic goals.</description>
    <arm_group_label>Liraglutide</arm_group_label>
    <other_name>Victoza®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glimepiride</intervention_name>
    <description>starting dose of 1 mg tablet (up-titrated as needed), once daily, as needed, after Week 12.</description>
    <arm_group_label>Sitagliptin +/- glimepiride</arm_group_label>
    <other_name>Amaryl®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>metformin tablets at a dose of ≥1500 mg per day</description>
    <arm_group_label>Sitagliptin +/- glimepiride</arm_group_label>
    <arm_group_label>Liraglutide</arm_group_label>
    <other_name>Fortamet®, Glucophage®, Glucophage® XR, Glumetza®, Riomet®, Metgluco®, Glycoran®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Type 2 diabetes mellitus.

          -  On stable dose of metformin monotherapy at a dose of at least 1500 mg per day for at
             least 12 weeks and a hemoglobin A1C ≥7.0% and ≤11.0%.

          -  Capable of using a liraglutide pen device.

        Exclusion criteria

          -  History of Type 1 Diabetes mellitus.

          -  Use of any oral antihyperglycemic agent (AHA) besides metformin, within the prior 12
             weeks of screening.

          -  Cardiovascular disorders within the past 3 months including acute coronary syndrome or
             new or worsening symptoms of coronary heart disease, coronary artery intervention,
             stroke, or transient ischemic neurological disorder.

          -  Impaired liver function.

          -  Impaired kidney function.

          -  History of malignancy or clinically important hematological disorder that requires
             disease-specific treatment (chemotherapy, radiation therapy, surgery) or, in the
             opinion of the investigator, is likely to recur during the duration of the study.

          -  History of leukemia, lymphoma, aplastic anemia, myeloproliferative or myelodysplastic
             diseases, thrombocytopenia, or malignant melanoma, regardless of the time since
             treatment.

          -  Pregnancy or breastfeeding, or intention to become pregnant or donate eggs within the
             projected duration of the study.

          -  Participation in another study with an investigational drug or device within 12 weeks
             prior to screening.

          -  History of hypersensitivity or any contraindication to sitagliptin, liraglutide,
             glimepiride, or metformin based upon the labels of the country of the investigational
             site.

          -  Participation in a weight loss program and not yet in maintenance phase, or starting
             of a weight loss medication (such as orlistat or phentermine) within the prior 8
             weeks.

          -  Surgery within the prior 4 weeks or major surgery planned during the study.

          -  Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine
             neoplasia syndrome type 2 (MEN 2).

          -  User of recreational or illicit drugs or recent history (within the last year) of drug
             abuse or increased alcohol consumption.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2011</study_first_submitted>
  <study_first_submitted_qc>February 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2011</study_first_posted>
  <results_first_submitted>February 5, 2013</results_first_submitted>
  <results_first_submitted_qc>February 5, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 15, 2013</results_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin +/- Glimepiride</title>
          <description>Sitagliptin 100 mg tablet once daily for 26 weeks. Participants continued their stable dose of metformin &gt;=1500 mg orally daily. Participants may have received glimepiride for glycemic control.</description>
        </group>
        <group group_id="P2">
          <title>Liraglutide</title>
          <description>Liraglutide subcutaneous injection once daily for 26 weeks (starting dose 0.6 mg daily up-titrated to 1.2 mg daily on Day 8). Participants continued their stable dose of metformin &gt;=1500 mg orally daily. Participants may have had their liraglutide dose uptitrated to 1.8 mg daily for glycemic control.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="326"/>
                <participants group_id="P2" count="327"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="275"/>
                <participants group_id="P2" count="257"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not specified</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin +/- Glimepiride</title>
          <description>Sitagliptin 100 mg tablet once daily for 26 weeks. Participants continued their stable dose of metformin &gt;=1500 mg orally daily. Participants may have received glimepiride for glycemic control.</description>
        </group>
        <group group_id="B2">
          <title>Liraglutide</title>
          <description>Liraglutide subcutaneous injection once daily for 26 weeks (starting dose 0.6 mg daily up-titrated to 1.2 mg daily on Day 8). Participants continued their stable dose of metformin &gt;=1500 mg orally daily. Participants may have had their liraglutide dose uptitrated to 1.8 mg daily for glycemic control.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="326"/>
            <count group_id="B2" value="327"/>
            <count group_id="B3" value="653"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.9" spread="10.0"/>
                    <measurement group_id="B2" value="57.6" spread="10.8"/>
                    <measurement group_id="B3" value="57.3" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="295"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="178"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c (A1C)</title>
          <description>A1C baseline values are presented for participants with data: Sitagliptin + metformin, n=325; liraglutide + metformin, n= 325; total population, n=650</description>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.2" spread="1.1"/>
                    <measurement group_id="B2" value="8.1" spread="0.9"/>
                    <measurement group_id="B3" value="8.2" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Plasma Glucose</title>
          <description>FPG baseline values are presented for participants with data: Sitagliptin + metformin, n=325; liraglutide + metformin, n= 325; total population, n=650</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="174.1" spread="43.7"/>
                    <measurement group_id="B2" value="172.9" spread="40.8"/>
                    <measurement group_id="B3" value="173.5" spread="42.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hemoglobin A1c (A1C)</title>
        <description>A1C is measured as percent. Thus, this change from baseline reflects the Week 26 A1C percent minus the Week 0 A1C percent.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>Per-protocol population defined as participants who had a measurement at baseline and a measurement after at least 24 weeks (i.e., 168 days) of treatment, and did not have any major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin +/- Glimepiride</title>
            <description>Sitagliptin 100 mg tablet once daily for 26 weeks. Participants continued their stable dose of metformin &gt;=1500 mg orally daily. Participants may have received glimepiride for glycemic control.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide</title>
            <description>Liraglutide subcutaneous injection once daily for 26 weeks (starting dose 0.6 mg daily up-titrated to 1.2 mg daily on Day 8). Participants continued their stable dose of metformin &gt;=1500 mg orally daily. Participants may have had their liraglutide dose uptitrated to 1.8 mg daily for glycemic control.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin A1c (A1C)</title>
          <description>A1C is measured as percent. Thus, this change from baseline reflects the Week 26 A1C percent minus the Week 0 A1C percent.</description>
          <population>Per-protocol population defined as participants who had a measurement at baseline and a measurement after at least 24 weeks (i.e., 168 days) of treatment, and did not have any major protocol violations.</population>
          <units>percent</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="253"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.32" spread="1.06" lower_limit="-1.42" upper_limit="-1.23"/>
                    <measurement group_id="O2" value="-1.42" spread="1.04" lower_limit="-1.51" upper_limit="-1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sitagliptin-based treatment paradigm was to be declared non-inferior to the liraglutide-based treatment paradigm in lowering A1C at Week 26 if the upper bound of 95% confidence intervals of between group difference was less than the non-inferiority margin of 0.4%.</non_inferiority_desc>
            <param_type>Difference in least squares mean</param_type>
            <param_value>0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG)</title>
        <description>Change from baseline at Week 26 is defined as Week 26 minus Week 0.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>Per-protocol population defined as participants who had a measurement at baseline and a measurement after at least 24 weeks (i.e., 168 days) of treatment, and did not have any major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin +/- Glimepiride</title>
            <description>Sitagliptin 100 mg tablet once daily for 26 weeks. Participants continued their stable dose of metformin &gt;=1500 mg orally daily. Participants may have received glimepiride for glycemic control.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide</title>
            <description>Liraglutide subcutaneous injection once daily for 26 weeks (starting dose 0.6 mg daily up-titrated to 1.2 mg daily on Day 8). Participants continued their stable dose of metformin &gt;=1500 mg orally daily. Participants may have had their liraglutide dose uptitrated to 1.8 mg daily for glycemic control.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG)</title>
          <description>Change from baseline at Week 26 is defined as Week 26 minus Week 0.</description>
          <population>Per-protocol population defined as participants who had a measurement at baseline and a measurement after at least 24 weeks (i.e., 168 days) of treatment, and did not have any major protocol violations.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="252"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.7" spread="46.2" lower_limit="-37.5" upper_limit="-29.9"/>
                    <measurement group_id="O2" value="-39.6" spread="40.3" lower_limit="-43.6" upper_limit="-35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in least squares mean</param_type>
            <param_value>5.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>11.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reaching A1C Goal of &lt;7.0%</title>
        <time_frame>Week 26</time_frame>
        <population>Per-protocol population defined as participants who had a measurement at baseline and a measurement after at least 24 weeks (i.e., 168 days) of treatment, and did not have any major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin +/- Glimepiride</title>
            <description>Sitagliptin 100 mg tablet once daily for 26 weeks. Participants continued their stable dose of metformin &gt;=1500 mg orally daily. Participants may have received glimepiride for glycemic control.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide</title>
            <description>Liraglutide subcutaneous injection once daily for 26 weeks (starting dose 0.6 mg daily up-titrated to 1.2 mg daily on Day 8). Participants continued their stable dose of metformin &gt;=1500 mg orally daily. Participants may have had their liraglutide dose uptitrated to 1.8 mg daily for glycemic control.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reaching A1C Goal of &lt;7.0%</title>
          <population>Per-protocol population defined as participants who had a measurement at baseline and a measurement after at least 24 weeks (i.e., 168 days) of treatment, and did not have any major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="253"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.8"/>
                    <measurement group_id="O2" value="72.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percent</param_type>
            <param_value>-9.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.4</ci_lower_limit>
            <ci_upper_limit>-1.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reaching A1C Goal of &lt;6.5%</title>
        <time_frame>Week 26</time_frame>
        <population>Per-protocol population defined as participants who had a measurement at baseline and a measurement after at least 24 weeks (i.e., 168 days) of treatment, and did not have any major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin +/- Glimepiride</title>
            <description>Sitagliptin 100 mg tablet once daily for 26 weeks. Participants continued their stable dose of metformin &gt;=1500 mg orally daily. Participants may have received glimepiride for glycemic control.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide</title>
            <description>Liraglutide subcutaneous injection once daily for 26 weeks (starting dose 0.6 mg daily up-titrated to 1.2 mg daily on Day 8). Participants continued their stable dose of metformin &gt;=1500 mg orally daily. Participants may have had their liraglutide dose uptitrated to 1.8 mg daily for glycemic control.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reaching A1C Goal of &lt;6.5%</title>
          <population>Per-protocol population defined as participants who had a measurement at baseline and a measurement after at least 24 weeks (i.e., 168 days) of treatment, and did not have any major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="253"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8"/>
                    <measurement group_id="O2" value="38.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percent</param_type>
            <param_value>-4.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.7</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety analyses were performed on the all participants as treated population (defined as participants who received at least 1 dose of study therapy). Participants were included in the reporting group corresponding to the actual study treatment received. Three participants randomized to therapy did not receive any study therapy.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin +/- Glimepiride</title>
          <description>Sitagliptin 100 mg tablet once daily for 26 weeks. Participants continued their stable dose of metformin &gt;=1500 mg orally daily. Participants may have received glimepiride for glycemic control.</description>
        </group>
        <group group_id="E2">
          <title>Liraglutide</title>
          <description>Liraglutide subcutaneous injection once daily for 26 weeks (starting dose 0.6 mg daily up-titrated to 1.2 mg daily on Day 8). Participants continued their stable dose of metformin &gt;=1500 mg orally daily. Participants may have had their liraglutide dose uptitrated to 1.8 mg daily for glycemic control.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="326"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Accidental death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="326"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Subcutaneous hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Malignant melanoma stage I</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Blue toe syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="326"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="326"/>
                <counts group_id="E2" events="42" subjects_affected="35" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="326"/>
                <counts group_id="E2" events="73" subjects_affected="63" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="326"/>
                <counts group_id="E2" events="25" subjects_affected="21" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="326"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="324"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="89" subjects_affected="41" subjects_at_risk="326"/>
                <counts group_id="E2" events="31" subjects_affected="15" subjects_at_risk="324"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

